about
Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseasesThe approval process for biosimilar erythropoiesis-stimulating agentsBiosimilars: Implications for health-system pharmacists.BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study.Formulary Selection Criteria for Biosimilars: Considerations for US Health-System PharmacistsAn Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.High-Throughput N-Glycan Analysis with Rapid Magnetic Bead-Based Sample Preparation.Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients.An expert opinion on the current treatment of anemia in patients with kidney disease.Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.The safety of switching between therapeutic proteins.Clinical safety of biosimilar recombinant human erythropoietins.Epoetin biosimilars in Europe: five years on.Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.Gel electrophoretic methods for the analysis of biosimilar pharmaceuticals using the example of recombinant erythropoietin.Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.Biosimilar ESAs: a comparative review.Biosimilars advancements: Moving on to the future.Structural identification of modified amino acids on the interface between EPO and its receptor from EPO BRP, human recombinant erythropoietin by LC/MS analysis.State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.Multivariate statistics for the differentiation of erythropoietin preparations based on intact glycoforms determined by CE-MS.Nanoparticulate Impurities in Pharmaceutical-Grade Sugars and their Interference with Light Scattering-Based Analysis of Protein Formulations.Biosimilar Retacrit® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) - non-interventional study.Stability of erythropoietin repackaging in polypropylene syringes for clinical use.Biosimilars Are Here: A Hospital Pharmacist's Guide to Educating Health Care Professionals on BiosimilarsQuality Control of Insulins and Biosimilar Insulins: What Do We Know?Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study.How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011.How bio-questionable are the different recombinant human erythropoietin copy products in Thailand?Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.Position Paper from the Portuguese Association of Hospital Pharmacists for biosimilar therapeutic antibodies.Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
P2860
Q27013577-7777F1B8-EA6A-4EA7-A6A6-BE4A72C8AD85Q34124734-A2872CF0-4F63-4BFE-A936-F269D2B0BF9BQ34372394-26D91399-BBB6-49A5-ABEF-952943EB64FEQ34485713-0F33375E-5598-40F3-9076-181F132911C8Q34612781-DFE56316-34C2-4D94-AF93-2923B6283639Q35762997-CE2B1CE1-A4FE-44D9-AAE1-80BCE203ECADQ36164390-5660A581-79AA-44B8-8E17-6876505DF078Q37391931-77F26098-966F-49BB-A3C4-7B40B89F914DQ37980546-C28BA81E-515D-44D9-9D54-A37A455BA584Q37999380-89D37C51-90AE-48A9-B1DE-CCC9D9488613Q38030980-CA3F63CA-73C1-4D9B-AD4C-094035D6DB80Q38033576-6A8ECED9-1E91-40E4-B78F-D0066E4A4178Q38067654-D12349FB-35F4-44FE-86B3-5AECF957D225Q38075798-D21594D0-1C6B-46F7-80BE-3C6659223B7BQ38083095-143F42CC-4113-40DB-A225-4CD311A8FCA8Q38151885-9943ED1C-455F-43AA-A153-FEB20767E90AQ38263040-035923F6-78DC-498A-9D4B-53A4A5EB0EDEQ38364577-9722FBC2-2C22-4D98-9E7E-6AC0E003EC50Q38433394-51D6693D-9EFD-4157-89E6-6758ECE6784BQ38556990-0B4077FC-B55F-4CC1-B276-CA464B0547D6Q39376945-9AAE1384-5F0B-49D2-BC18-687AE71FC57AQ41558985-119FE8B5-00B9-46C2-B11E-05B4674A408BQ41784569-98CBE31F-11A2-4DFB-8F8A-93C47FDD58CAQ41906810-0A098ADB-AF2B-4514-AC87-24DA7ED81C21Q42385440-6D09F7BF-166A-453E-B1D4-070B706C7C5FQ42482260-809CD4AF-3FC9-4A5F-BC4F-C2272AFD0168Q42803012-D7252F7A-7871-4A41-B794-81D467B71BECQ45074626-22DC516B-B414-4001-8F99-30C53B836D5EQ46120837-5CBDAA6D-1C96-4E68-AFEE-6C85C5840C92Q48287588-E79E116D-9C7B-4A42-9B8E-8EB83C70AD45Q50107702-6761C2AD-DAE3-41E9-8FAA-E2772EDA528BQ51320460-F3F5A6F2-C44B-4B42-8524-40ACA811C3AEQ54959955-F53288D1-2BA0-46E9-A34C-206BE286A942
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Quality of original and biosimilar epoetin products
@ast
Quality of original and biosimilar epoetin products
@en
Quality of original and biosimilar epoetin products
@nl
type
label
Quality of original and biosimilar epoetin products
@ast
Quality of original and biosimilar epoetin products
@en
Quality of original and biosimilar epoetin products
@nl
prefLabel
Quality of original and biosimilar epoetin products
@ast
Quality of original and biosimilar epoetin products
@en
Quality of original and biosimilar epoetin products
@nl
P2093
P2860
P1476
Quality of original and biosimilar epoetin products
@en
P2093
Abdul H H Basmeleh
Andrea Hawe
Govert W Somsen
Huub Schellekens
Liliana Joachin-Rodriguez
Vera Brinks
Wim Jiskoot
P2860
P304
P356
10.1007/S11095-010-0288-2
P577
2010-10-01T00:00:00Z